Boehringer Ingelheim bags a contract manufacturer, adding muscles for cancer vaccine, oncolytic virus programs
As Boehringer Ingelheim grows its pipeline of next-gen cancer therapies, it’s also beefing up the capacity to refine and make them.
The pharma giant is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
